T he Beers Criteria were first introduced in 1991. 1 Since then, widespread efforts to educate clinicians about the criteria and to use them in quality improvement activities have had meaningful impacts on the quality of care of older adults. Use of many medications included in the Beers Criteria has declined, others have been withdrawn from the market, and there is greater (although still too little) appreciation of the unique considerations that should be applied when prescribing for older adults. [2] [3] [4] [5] [6] [7] Yet, implementation and uptake of the Beers Criteria have not been without problems. Many clinicians misunderstand the purpose of the criteria, mistakenly believing that the criteria deem all uses of the listed drugs to be universally inappropriate. Health systems have often reinforced this perception, implementing quality improvement and decision support systems that implicitly consider any use of these medications to be problematic. In addition, some payors have adopted prior authorization requirements for Beers Criteria medications, which may be misapplied by the payor and/or misinterpreted by the prescribing clinician. 8 Implementation of the criteria in inflexible, dogmatic ways can breed resentment and lack of faith in the recommendations. 2, 9, 10 Moreover, they can negatively affect quality of care by restricting access to medications included in the criteria that are being used in appropriate ways and create troublesome and unnecessary burdens for prescribers. 2 The goal of this article is to improve how patients, clinicians, health systems, and payors use the AGS 2015 Beers Criteria. Guidance is provided on how the criteria are intended to be used, and recommendations are made for implementing them in a manner that reflects this intent. The hope is that patients, caregivers, clinicians, health systems leaders, and payors will use this guidance to direct implementation efforts that yield maximal benefits from the AGS 2015 Beers Criteria while minimizing unintended harms. To this end, the AGS is also developing educational materials customized to different audiences that are based on the recommendations in this article.
METHODS
To coincide with the 2015 update of the Beers Criteria, the AGS convened a workgroup consisting of four members of the update panel (MAS, JB, CD, RL), the Chief Executive Officer of the AGS (NL), and the chair of the AGS Clinical Practice Committee (PM). The workgroup was tasked with developing guidance on the intended use and implementation of the AGS 2015 Beers Criteria and authoring the current report. The workgroup convened using conference calls and e-mail communication first to develop a list of principles to guide optimal use of the criteria, with a particular focus on the "drugs to avoid" elements of the criteria, and then to author the current report built around these principles. During each of these steps, feedback was solicited from stakeholders (listed in the acknowledgments). The penultimate draft of the report was sent for outside review and reviewed internally by AGS leaders, with final approval of the AGS Board of Directors.
KEY PRINCIPLES TO GUIDE OPTIMAL USE OF THE AGS 2015 BEERS CRITERIA
Seven key principles that should be used to guide optimal use of the criteria are shown in Table 1 and explained here.
Key Principle 1: Medications in the AGS 2015 Beers Criteria are potentially inappropriate, not definitely inappropriate
There is a common misperception that any use of a medication in the Beers Criteria is considered inappropriate. This is not correct. The Beers Criteria comprise medications that have an unfavorable balance of benefits and harms for many older adults, particularly in light of available pharmacological and nonpharmacological alternatives. In some cases the drug is almost always a poor choice. However, there are some older adults in whom use of these medications is appropriate. Thus, Beers Criteria medications are "potentially inappropriate" and merit special scrutiny but are not universally inappropriate in all patients.
Key Principle 2: Read the rationale and recommendations statements for each criterion. The caveats and guidance listed there are important Many medications are considered potentially inappropriate only in certain circumstances or in most circumstances but with some exceptions. These distinctions are highlighted in the rationale and recommendations statements for each criterion and are vital for proper interpretation and use of the criteria ( Figure 1 ). As in all prescribing decisions, clinical judgment is required. As noted in Key Principle 1, a drug that the criteria consider "potentially inappropriate" may not always be a bad choice. Conversely, just because a medication is subject to an exemption (or not included in the criteria at all) does not automatically mean it is a good choice. The AGS 2015 Beers Criteria capture only a small percentage of the total burden of medication-related problems in older adults. 11, 12 The criteria work best when used as a starting point to review and discuss an individual's entire medication regimen. This includes individualized inquiry into and assessment of medication indication, effectiveness, adverse effects, cost, and adherence, and concordance of the medication regimen with an individual's abilities and goals of care. 2, 14, 15 Programs that restrict access to Beers Criteria medications should be carefully targeted and give the prescribing clinician, who is in the best position to evaluate the appropriateness of medications for individual patients, the opportunity to provide a valid clinical rationale that permits coverage.
Key Principle 7: The AGS 2015 Beers Criteria are not equally applicable to all countries
The AGS 2015 Beers Criteria were developed principally based on medications available in the United States. Medications may be available in other countries that are potentially inappropriate but are not included in the list. 16, 17 Prior versions of the Beers Criteria have been adapted for several countries. In the absence of country-specific adaptations of the Beers Criteria, in most cases it is reasonable to use broad-based categories included in the criteria to identify PIMs, for example benzodiazepines and strongly anticholinergic drugs.
APPLICATION OF KEY PRINCIPLES-OVERVIEW
The following section suggests how patients, clinicians, and health systems and payors can apply the key principles to improve pharmaceutical care of older adults. These are summarized in Table 2 , and a case example is provided in Figure 2 .
Application of key principles for patients and caregivers

Talking with clinicians about AGS 2015 Beers Criteria medications
Older adults should not stop taking a drug just because it is included in the Beers Criteria. Instead, they should discuss with their clinicians whether that medication is the right choice for them and ask whether there are safer or more-effective alternatives. As part of this conversation, patients should be prepared to discuss symptoms that they think might be due to their medication(s), review how much the medication(s) seems to be helping them, and raise any other concerns about the medication. Similarly, patients should discuss with their clinicians the indication and planned duration of use for the medication. More than one perspective can be helpful, and it can be particularly useful to discuss these topics with one's prescriber(s), pharmacist(s), and other healthcare providers.
Engaging patients and caregivers as active participants in care
Care is improved when patients and caregivers are actively involved in their care. 18 tions comprise only a small proportion of problematic prescribing, active engagement in pharmacotherapy should extend beyond Beers Criteria medications to cover the individual's entire medication regimen. Engagement in pharmacotherapy includes people learning about their medications, the reasons they are taking these medications, and what adverse effects (side effects) they can cause. A good source for this information is the National Library of Medicine's MedlinePlus website (http://www.nlm.nih.gov/ medlineplus/druginformation.html). Optimal patient involvement also includes periodically reviewing their medications with their clinicians, including prescribers and pharmacists. In these reviews, patients and caregivers should report any problems with their medications, including potential adverse events, perceived lack of effectiveness, and problems with adherence or cost. Such discussions should occur at least annually and any time a new medication is prescribed.
True patient engagement involves not just an activated patient and caregiver, but also the willingness and ability of clinicians to engage patients in shared decision-making and incorporate patient preferences and values into their treatment recommendations. At times this may involve using an AGS 2015 Beers Criteria medication that the clinician might otherwise avoid.
Patient-and community-focused organizations
Organizations that have expertise and a focus on communicating with older adults and caregivers can play an important role in educating people and their communities about the AGS 2015 Beers Criteria and promoting their appropriate uptake and use.
Application of key principles for clinicians
The 2015 AGS Beers Criteria as a "warning light"
The AGS 2015 Beers Criteria are not intended to identify medications that are uniformly inappropriate but rather to call attention to medications that are commonly problematic and thus should be avoided in most older adults. A good way to think about the role of the criteria is that when a clinician considers prescribing a Beers Criteria medication, a "warning light" should go off in his or her head. This warning light should remind the clinician of the potentially unfavorable balance of benefits and harms of the medication and prompt consideration of whether other treatment approaches would be better. Questions to address include: Why is the patient taking the drug, and is it truly needed? Are there safer or more-effective alternatives for the patient? Does this patient have particular characteristics that increase or mitigate the risk of this medication?
This heightened awareness not only should occur at the time the drug is initially prescribed, but should also continue over time and prompt ongoing monitoring to assess whether the therapy is effective or causing adverse effects. In many cases, this heightened awareness should lead to periodic attempts to discontinue or reduce doses of the medication. Even for people who have tolerated Beers Criteria medications, adverse effects or reduced effectiveness can occur years into therapy because of the physiology of aging and other changes in clinical status.
Assessing adverse effects
Many of the adverse effects of AGS 2015 Beers Criteria medications can be subtle yet important. For example, AGS 2015 Beers Criteria medications may induce mild decreases in cognitive function that can affect daily functioning and quality of life or cause small changes in balance and gait stability that increase the risk of falls. These adverse events may not be recognized or reported by patients or their caregivers, or may be mistakenly attributed by patients, caregivers, or clinicians as symptoms of an underlying condition or simply a result of old age. [20] [21] [22] Careful inquiry is often necessary, coupled with attention to the adage that "any symptom in an older adult is a medication side effect until proven otherwise." Often the only way to determine if an individual's symptoms are due to a drug is to withdraw the medication and see whether the symptoms improve, informally or as part of a moresystematic N-of-1 trial. 23 How the AGS 2015 Beers Criteria fit into the larger picture of improving prescribing for older adults Many serious adverse drug events in older adults are caused by medications not included in the Beers Criteria. 11 Common culprits such as warfarin are not listed as drugs to avoid in the AGS 2015 Beers Criteria because for many older adults their benefits outweigh their potential harms. 24 Nonetheless, attention to AGS 2015 Beers Criteria medications should not detract from closely monitoring and preventing adverse events from other high-risk medications. Similarly, attention to the AGS 2015 Beers Criteria should not detract from evaluating and addressing other concerns of fundamental importance including (but not limited to) medication reconciliation, medication adherence, unnecessary medication use, and underuse of potentially beneficial medications. Discussions about AGS 2015 Beers Criteria medications can be an excellent entr ee to a broader discussion that addresses these other aspects of medication use.
The AGS 2015 Beers Criteria are complementary to other explicit criteria used to assess medication appropriateness, such as the Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) criteria. [25] [26] [27] Similarly, the AGS 2015 Beers Criteria should be used to complement, rather than compete with, criteria that evaluate other domains of prescribing quality, for example the Screening Tool to Alert doctors to the Right Treatment (START) criteria, which evaluate underuse of potentially beneficial medications in older adults. 28 Finally, the AGS 2015 Beers Criteria focus on medications that are particularly problematic for older adults. Many medications that are problematic across the age spectrum are not included but merit close scrutiny as well.
Talking with patients and their caregivers about AGS 2015 Beers Criteria medications
The criteria can provide a useful tool for engaging individuals and caregivers in discussion about their medications. They can be used to start a larger conversation about effectiveness, adverse effects, cost, adherence, and goals of care for the person's entire medication regimen. They can also be a useful adjunct for helping physicians counsel people about stopping medications that appear on the list, particularly if they are reluctant to stop those medications.
Talking with other clinicians about AGS 2015 Beers Criteria medications
Primary care and generalist clinicians should not automatically defer to their specialist colleagues if that specialist
Patient
Ms. A reviews her medications on Medline Plus (http://www.nlm.nih.gov/medlineplus/druginformation.html). She has had lowgrade but persistent malaise and anorexia for years. Before, she thought these symptoms were simply a part of getting old, but she now realizes that they can be adverse effects of amiodarone. She reports these symptoms to her physician and asks whether they could be a side effect of amiodarone. She also notes that this drug is on the Beers list and asks her physician whether another drug might be safer or more effective. Clinician Dr. B remembers that amiodarone is on the AGS 2015 Beers Criteria because of its multiple toxicities, and is considered a potentially inappropriate medication for the management of atrial fibrillation because there are safer alternatives. She asks Ms. A about common and serious adverse effects of amiodarone and elicits her symptoms of malaise and anorexia. Dr. B e-mails Ms. A's cardiologist to inform him of Ms. A's symptoms and discuss options for using another medication; he concurs this would be reasonable. Dr. B contacts Ms. A to suggest substituting another medication for management of her atrial fibrillation and following her symptoms to see whether they improve. Health system
The health system in which Dr. B practices establishes a clinical decision support system through its electronic medical record. Recognizing that Ms. A is taking amiodarone, the system sends an alert to Dr. B shortly before the visit. The alert notes that the drug is an AGS 2015 Beers Criteria medication, briefly describes the rationale for its inclusion on the Beers list, and links to easy-to-use resources about symptoms and signs of amiodarone toxicity and alternative medications to manage atrial fibrillation.
Case Example Ms. A is an 82-year-old woman who is visiting Dr. B for the first time.
Dr. B reviews the patient's medication list and sees that she is taking amiodarone to treat atrial fibrillation. She has been on this medication for several years and reported "no problems" with it during visits with her previous provider. prescribed an AGS 2015 Beers Criteria medication, and vice versa. 21 Rather, the Beers list can provide a foundation for a discussion between clinicians of whether the person truly needs the medication and whether there are safer and more-effective alternatives.
Stopping AGS 2015 Beers Criteria medications
Many Beers medications should not be stopped abruptly because of the high risk of precipitating a withdrawal reaction. A good rule of thumb is that a drug dose is usually safe to taper down at the same rate that it can safely be tapered up. 29 Role of healthcare professionals other than prescribers and pharmacists Registered nurses and other healthcare professionals can play an important role even in the absence of direct prescribing authority. For example, nurses often see and assess for medication problems in the home, hospital, postacute, and long-term care settings, and often help in making a decision to give or not give a Beers medication prescribed on an as-needed basis. As such, they are important partners in identifying, addressing, and educating people about potential problems with AGS 2015 Beers Criteria medications. 30 
Application of key principles for health systems and payors
Use in clinical decision support systems
The AGS 2015 Beers Criteria are well suited to clinical decision support, and studies have shown they can be deployed to good effect in this setting. 31 Decision support systems are likely to be most useful when they suggest alternative pharmacological and nonpharmacological therapies that can be used in place of Beers Criteria medications.
Use in monitoring provider-and systems-level prescribing practices
The AGS 2015 Beers Criteria are useful for monitoring quality of care across populations of clinicians and patients. Because these medications are inappropriate for most older adults, lower rates of use are preferable in most settings. However, because there are circumstances in which use of these medications is reasonable, monitoring systems should not judge care to be inappropriate for any specific individual on the basis of that person taking a Beers Criteria medication. For similar reasons, the target rate of use for performance measurement programs should not be 0%. Performance measurement systems should also be careful to integrate performance measures for Beers Criteria medications with measures that address other important domains of quality in pharmaceutical care. Focusing clinician attention exclusively on Beers Criteria medications may result in insufficient attention to other aspects of prescribing such as medication monitoring, medication adherence, and underuse of medications that for many people are more important than the Beers Criteria.
Use in prior authorization and insurance coverage decisions
There is a reasonable role for health plan design to screen for AGS 2015 Beers Criteria medications for extra attention and review. Some medications included in the criteria are particularly harmful or have few reasonable indications, justifying tight controls. However, many medications in the criteria can have appropriate uses. Excessive restrictions on use of these medications and ignoring caveats listed in the criteria may harm people by limiting their access to therapies that can help them. Moreover, excessive restrictions cause undue burden on prescribers and can inappropriately frame the Beers Criteria in a punitive light. As a result, in most cases in which AGS 2015 Beers Criteria medications require authorization, clinicians should have access to a streamlined process to justify their use. (This streamlined process should ideally be available across a range of prior authorization issues, not just for AGS 2015 Beers Criteria medications). When AGS 2015 Beers Criteria medications are flagged for approval or review, appropriate alternative therapies should be suggested where possible.
CONCLUSIONS
The ability of the AGS 2015 Beers Criteria to improve care depends on their being applied in a thoughtful manner. Individuals, clinicians, and health systems are encouraged to use the key principles outlined in this article to guide how they implement the Beers Criteria so as to improve outcomes while minimizing unintended harms. Conflicts of interest: Dr. Beizer is an author and editor for LexiComp, Inc. Dr. Mulhausen is the Chief Medical Officer of Telligen, Inc. Dr. Steinman is a consultant for Iodine.com, a web start-up company.
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